Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Adma Biologics (ADMA) Long-Term Debt Issuances (2017 - 2023)

Historic Long-Term Debt Issuances for Adma Biologics (ADMA) over the last 8 years, with Q4 2023 value amounting to $135.0 million.

  • Adma Biologics' Long-Term Debt Issuances changed N/A to $135.0 million in Q4 2023 from the same period last year, while for Dec 2024 it was $135.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $135.0 million for FY2023, which is 1103.79% down from last year.
  • Per Adma Biologics' latest filing, its Long-Term Debt Issuances stood at $135.0 million for Q4 2023.
  • In the past 5 years, Adma Biologics' Long-Term Debt Issuances registered a high of $151.8 million during Q1 2022, and its lowest value of $12.5 million during Q1 2020.
  • Over the past 4 years, Adma Biologics' median Long-Term Debt Issuances value was $45.0 million (recorded in 2019), while the average stood at $71.8 million.
  • Examining YoY changes over the last 5 years, Adma Biologics' Long-Term Debt Issuances showed a top increase of 7222.22% in 2020 and a maximum decrease of 7222.22% in 2020.
  • Quarter analysis of 4 years shows Adma Biologics' Long-Term Debt Issuances stood at $45.0 million in 2019, then plummeted by 66.67% to $15.0 million in 2020, then surged by 911.67% to $151.8 million in 2022, then decreased by 11.04% to $135.0 million in 2023.
  • Its Long-Term Debt Issuances stands at $135.0 million for Q4 2023, versus $151.8 million for Q1 2022 and $15.0 million for Q4 2020.